You are here

Intravenous Form of Methylnaltrexone Gains Fast Track Designation

MADISON, N.J. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--July 17, 2006--Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE - News), and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX - News) today announced that the intravenous form of methylnaltrexone being investigated for the treatment of postoperative ileus, a serious impairment of gastrointestinal function that delays recovery and can prolong hospitalization, has been designated for Fast Track status by the U.S. Food and Drug Administration (FDA). The FDA Fast Track designation facilitates development and expedites regulatory review of drugs that the FDA recognizes to potentially address an unmet medical need for serious or life-threatening conditions.

Methylnaltrexone is an investigational drug that is being studied as a treatment for the peripheral side effects of opioid analgesics that does not affect the pain relief provided by these analgesics. Methylnaltrexone is being developed in three dosage forms: subcutaneous and oral forms as treatment platforms for opioid-induced constipation, and an intravenous form for postoperative ileus. In December 2005, Wyeth and Progenics Pharmaceuticals entered into a collaboration agreement to develop and commercialize methylnaltrexone.

With Fast Track designation for methylnaltrexone for the treatment of postoperative ileus, the companies can take advantage of several programs at the FDA to streamline the regulatory review process and to work more closely with the Agency on product development plans. Sponsors of Fast Track products are also eligible to submit portions of a New Drug Application (NDA) on a rolling basis, enabling FDA to commence review of individual sections of the application before receiving the complete application. Additionally, the sponsors may request that methylnaltrexone be considered for priority review (six-month versus standard ten-month review).

Progenics Pharmaceuticals has completed a phase 2 study of intravenous methylnaltrexone showing accelerated gastrointestinal recovery in patients following segmental colectomies. In the 2006 third quarter, Wyeth and Progenics plan to initiate global phase 3 studies in patients at high risk for developing postoperative ileus. An NDA submission is planned for the intravenous form of methylnaltrexone in late 2007 or early 2008.

Postoperative ileus is a major contributor to prolonged hospital stays and has an impact on health care costs. Because many postoperative patients cannot tolerate oral intake, including medications, intravenous methylnaltrexone may represent an important therapy for these patients.

Source: Wyeth Pharmaceuticals and Progenics Pharmaceuticals

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function